Terazosin for energy levels in ALS
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This study tests whether a blood pressure medicine called terazosin can boost energy production in cells of people with ALS, potentially slowing the disease. It involves taking the medication daily for a period and monitoring safety and effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have a diagnosis of ALS and your symptoms started within the last 3 years.
- Your breathing function must be at least 65% of what's expected for someone your age.
- You must be able to swallow pills.
- If you take riluzole or edaravone, you must have been on a stable dose for at least 4 weeks (or one cycle for edaravone) before the study starts.
- You must be willing to use highly effective contraception during the study and for 80 days after your last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a drug called tazbentetol can help people with ALS. It aims to see if it is safe and slows the disease's progression.
This study tests a supplement called acetyl-L-carnitine (ALCAR) to see if it can slow the progression of ALS. It is for people in the early stages of the disease who are already taking riluzole and have good lung and muscle function.
This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.
This trial tests a new drug called VTx-002 to see if it is safe and tolerable for people with ALS. You may be able to join if you have had symptoms for less than 18 months and have a caregiver who can help.
This trial tests whether adding two supplements (EH-301 and N-acetylcysteine) to the standard ALS medicine Riluzole can help slow the disease. It is for people diagnosed with ALS within the last 18 months who still have good breathing and daily function.
This Phase 2 study tests whether dazucorilant can slow or improve outcomes in people with amyotrophic lateral sclerosis (ALS) who are likely to progress more quickly. You may be able to join if you meet specific ALS type and risk-score requirements and your health tests and medications fit the study rules.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.